Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IGC Pharma (IGC) Net Cash Flow (2016 - 2025)

IGC Pharma (IGC) has disclosed Net Cash Flow for 16 consecutive years, with $646000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Net Cash Flow rose 341.95% to $646000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was -$473000.0, a 67.91% increase, with the full-year FY2025 number at -$786000.0, up 60.54% from a year prior.
  • Net Cash Flow was $646000.0 for Q3 2025 at IGC Pharma, up from $24000.0 in the prior quarter.
  • In the past five years, Net Cash Flow ranged from a high of $13.6 million in Q1 2021 to a low of -$2.5 million in Q4 2021.
  • A 5-year average of $12052.6 and a median of -$1.1 million in 2024 define the central range for Net Cash Flow.
  • Biggest YoY gain for Net Cash Flow was 583.14% in 2021; the steepest drop was 1194.24% in 2021.
  • IGC Pharma's Net Cash Flow stood at -$2.5 million in 2021, then surged by 32.65% to -$1.7 million in 2022, then increased by 0.96% to -$1.6 million in 2023, then surged by 34.75% to -$1.1 million in 2024, then skyrocketed by 160.04% to $646000.0 in 2025.
  • Per Business Quant, the three most recent readings for IGC's Net Cash Flow are $646000.0 (Q3 2025), $24000.0 (Q2 2025), and -$67000.0 (Q1 2025).